News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Chugai Pharmaceutical Co., Ltd. (Japan) and Taisho Pharmaceutical Release: Eldecalcitol, an Active Vitamin D3 Derivative, Reduces Incidence of New Vertebral Fractures in Osteoporosis Patients in Phase III Clinical Trial


12/18/2008 8:49:44 AM

Tokyo, Dec 16, 2008 (JCN Newswire) - Chugai Pharmaceutical Co., Ltd. and Taisho Pharmaceutical Co., Ltd. announced today that the active vitamin D3 derivative being co-developed by the two companies for treatment of osteoporosis (generic name: eldecalcitol; Chugai development code: ED-71, Taisho development code: CT-081) significantly reduced the incidence of new vertebral fractures in osteoporosis patients in a randomized, double-blind, comparative trial. Detailed study results will be published in a medical journal and announced at a medical conference.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES